Edesa Biotech, Inc. EDSA
We take great care to ensure that the data presented and summarized in this overview for Edesa Biotech, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EDSA
Top Purchases
Top Sells
About EDSA
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Insider Transactions at EDSA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,785
+3.87%
|
-
|
|
May 01
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,083
+2.63%
|
-
|
|
Apr 01
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+2.85%
|
-
|
|
Mar 25
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.44%
|
$20,000
$4.0 P/Share
|
|
Mar 01
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,765
+2.5%
|
-
|
|
Feb 01
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,978
+2.76%
|
-
|
|
Jan 08
2024
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,908
+2.77%
|
-
|
|
Aug 04
2023
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,300
+12.52%
|
-
|
|
Aug 04
2023
|
Michael J Brooks President |
BUY
Grant, award, or other acquisition
|
Direct |
93,200
+42.97%
|
-
|
|
Aug 04
2023
|
Stephen Lemieux Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,400
+50.0%
|
-
|
|
Jan 10
2023
|
Velden Peter Van Der > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
152,345
-7.9%
|
$304,690
$2.63 P/Share
|
|
Jan 09
2023
|
Velden Peter Van Der > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
145,129
-7.0%
|
$290,258
$2.66 P/Share
|
|
Nov 02
2022
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
456,524
+29.41%
|
$456,524
$1.12 P/Share
|
|
Nov 02
2022
|
Kathi Niffenegger Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
8,888
+45.34%
|
$8,888
$1.12 P/Share
|
|
Nov 02
2022
|
Michael J Brooks President |
BUY
Grant, award, or other acquisition
|
Direct |
4,239
+12.21%
|
$4,239
$1.12 P/Share
|
|
Jun 30
2022
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+3.25%
|
$20,000
$1.6 P/Share
|
|
Jun 29
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
3,000
+10.26%
|
$3,000
$1.49 P/Share
|
|
Jun 16
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
3,000
+11.43%
|
$3,000
$1.61 P/Share
|
|
May 27
2022
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.86%
|
$5,000
$1.92 P/Share
|
|
May 25
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
3,500
+14.74%
|
$3,500
$1.74 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 230K shares |
|---|---|
| Open market or private purchase | 5K shares |